Showing 1,523 results

Filters Content type: News, Editors' picks, About HIV Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

Pharmaceutical industry

GSK eyes prime FTSE 100 slot for standalone HIV drugs business

Editor's pick
Reuters
26 October 2014
Pharmaceutical industry

GlaxoSmithKline weighs an IPO for HIV-focused ViiV as it sharpens the budget axe

Editor's pick
FierceBiotech
22 October 2014
Pharmaceutical industry

Juncker seen making U-turn on medicines policy

Editor's pick
EurActiv
17 October 2014
Hepatitis C treatment

Unique 'pay if you clear' proposal for new hepatitis drug

Editor's pick
BBC
15 October 2014
New & experimental hepatitis C treatment

Fair Pricing Coalition Urges a Uniform Price for Curative Hepatitis C Treatment

Editor's pick
Fair Pricing Coalition
15 October 2014
Pharmaceutical industry

If AbbVie Discounts its Hep C Drug, Would Pricing Reach a Tipping Point?

Editor's pick
Wall Street Journal
15 October 2014
New & experimental hepatitis C treatment

In a surprise move, Bristol-Myers drops U.S. approval plans for hep C drug

Editor's pick
Fierce Biotech
7 October 2014
Pharmaceutical industry

Europe: Pharma industry denies it lobbied for medicines to move to DG Enterprise

Editor's pick
EurActiv
1 October 2014
Pharmaceutical industry

J&J makes a splash in hep C with a $1.75B deal for Alios

Editor's pick
Fierce Biotech
1 October 2014
New & experimental HIV treatments

Gilead’s investigational tenofovir alafenamide (TAF)-based single tablet HIV regimen meets 48-week primary objective in two Phase 3 studies

Editor's pick
Gilead press release
25 September 2014
New & experimental HIV treatments

Gilead Sciences: A Preview of Important HIV Drug Study Results

Editor's pick
The Street
23 September 2014
Health services & systems

US: How Insurers Are Finding Ways to Shift Costs to the Sick

Editor's pick
New York Times
18 September 2014
Access to healthcare

Gilead’s Proposed Hepatitis C Medicines License: How Badly Will it Miss the Target?

Editor's pick
Infojustice
17 September 2014
Hepatitis C treatment

Access to sofosbuvir in middle-income countries

Editor's pick
I-MAK
17 September 2014
Pharmaceutical industry

Open Letter to President-elect Jean-Claude Juncker on move of medicinal products and health technologies to the portfolio of the Commissioner for internal market and industry

Editor's pick
EATG
17 September 2014
Pharmaceutical industry

Gilead to raise price for new hepatitis C drug above $84000

Editor's pick
Reuters
15 September 2014
New & experimental HIV treatments

New medicines in development give hope to patients with HIV/AIDS

Editor's pick
Pharmaceutical Research and Manufacturers of America
11 September 2014
Access to healthcare

Gilead close to sending $84,000 drug to poor countries

Editor's pick
Bloomberg
9 September 2014
Side effects

New Tenofovir Alafenamide Combo Pill Has Less Effect on Kidneys and Bones

Editor's pick
HIVandhepatitis.com
9 September 2014
Resistance

Longer time to virological failure and less drug resistance seen in people taking Atripla than in people taking separate drugs

News
9 September 2014
Access to healthcare

Poor patients in India facing HIV/AIDS drug shortages

Editor's pick
Reuters
5 September 2014
New & experimental HIV treatments

EU marketing authorization for ViiV Healthcare HIV drug Triumeq

Editor's pick
Pharma Letter
4 September 2014
New & experimental HIV treatments

Aiming For HIV's Weak Spot - The new generation of gp120 entry inhibitors

Editor's pick
C&EN - Chemical and Engineering News
2 September 2014
New & experimental HIV treatments

FDA Approves New Single-Tablet HIV Regimen, Triumeq

Editor's pick
Aidsmeds.com
26 August 2014